AUTHOR INDEX Articles under the rubric Of Nephrology and Nephrologists are referred to by journal number, a colon, and page numbers. Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number. Page references to Supplement 1 (April 2000) and Supplement 2 (June 2000) are preceded, respectively, by S1: and S2:. Abbott, K.C., 237 Bastani, B., 146 Buchalter, M., 753 Abrass, C.K., 544 Beach, K., 477 Budde, K., 3:E12 Abt, A.B., 533 Becker, B.N., 653 Biihler, M., 624 Abu-Alfa, A.K., 1076 Becker, Y.T., 653 Bunchman, T.E., 958 Adams, J.E., 227 Bellin, M-F., 745 Burkart, J.M., 506 Afzal, A.R., 211 Bellovich, K., 606 Agodoa, L., 157, 352 Beltramo, D., 941 Caglioti, A., 448 Agodoa, L.Y.C., 80 Bengal, R., 930 Cain, J.A., 275 Agraharkar, M., 319 Benini, R., 1155 Caldeira, FE.R., 839 Ahmad, S., 477, 493 Bennett, W.M., 333 Callan, R., 493 Ahuja, T.S., 884 Benz, R.L., 1052 Calleja, Y., 606 Albizta, R., 137 Berden, J.H.M., 845 Cameron, J.I., 629 Alegre, R., 141 Berger, R., 1149 Campbell, G.A., 319 Allen, A.C., 551 Berl, T., 6:xIvii-l Cao, P.G., 211 Alon, U.S., 1111 Berland, Y., 13 Cao-Huu, T., 5:E21 Alt, P.S, $1:141 Bernardini, J., 1104 Capodicasa, L., 1144 Anastasio, P., 1144 Bia, M.J., 1076 Carey, S., 482 Anderson, R.J., 1127 Birk, C.G., 1089 Caridi, G., 44 Anderson, S., 923 Bitzan, M.M., 354 Carlson, L., 482 André, M.B., 839 Blagg, C.R., 493 Carrefio, A., 137, 141 Andreoli, S.P., $1:31 Blake, P.G., 506 Carroll, L.E., 533 Andrés, A., 141 Blake, R., 506 Cartwright, J. Jr., 4:E15 Andresdottir, M.B., 2:E6 Block, G.A., 1226 Caslake, M.J., 852 Andreucci, M., 448 Blowey, D.L., 1111 Cesana, B., 1135 Andreucci, V.E., 448 Boeschoten, E.W., 69 Chadha, V., 1111 Argyle, R., 112 Bohmig, G.A., 667 Chan, T.M., 644 Arisz, L.A., 819 Bolton, W.K., 266 Chang, J-M., 189 Arora, N., 301 Border, W.A., 773 Chang, S-H., 313 Arruda, J.A.L., 739 Borucki, M., 884 Chapman, A., 35 Arumugam, R., 301 Bos, W.J.W., 819 Chapman, A.B., 427 Asaka, M., 6:E31 Bosch, J.P., 2:xlvi—xlviii Charney, D., 173 Aschauer, M., 529 Charney, D.A., 1193 Boulton-Jones, J.M., 852 Ashby, V.B., 80 Chau, K.F., 660 Bourgoignie, J., 5:E24 AAsshhfmoorrde,, RS..GD..,, 789267 Bouvier, C., 13 CChheany,a mCa-,H .,K .,5 2 1186 Asif, A., 3:E10 Boyle, P., 157, 352 Chen, G., 408 Braam, B., 202 Assmann, K.J.M., 2:E6 Chen, H-C., 189 Ates, K., 1207 Braden, G.L., 878 Cheng, C-H., 52 Atkins, C., $1:19 Brand, J.L., $1:81 Chertow, G.M., 557, 1044, 6:E30 Brazy, P.C., 653 Atkins, R.C., 418 Chevalier, R.L., 775 Azzopardi, J., 708 Brezina, M., 122, 832 Chin, W.D.N., 802 Brier, M.E., 89 Choi, P.C.L., 392 Briggs, D., 157, 352 Choudhury, D., 365 Bahlmann, F., 21 Briggs, W., 282 Chrystyn, H., 827 Bahner, U., 347 Brophy, P.D., 958 Ciardi, M.R., 44 Bailie, G.R., | Brosnahan, G.M., 427 Cirillo, E., 1144 Balabanian, M., 963 Brown, W.W., S1:3 Clase, C.M., 500 Barats, M.S., 963 Bruin, S., 819 Claudon, M., 5:E21 Bargman, J.M., 506 Bryant, J.L., 408 Clayman, R.V., 720 Barrios, R., 4:E15 Buccianti, G., 157, 352 Coffin, R., 275 American Journal of Kidney Diseases, Vol 35, No 6 (June), 2000: pp 1251-1272 1252 AUTHOR INDEX Cohen, G., 1117 Dominguez-Gil, B., 137 Fujita, T., 401 Cohen, J., 58 Dominguez-Gil, B., 141 Furth, S.L., 282 Cole, J.J., 493 Dossetor, J.B., 1002 Cole, M.J., 122 Druml, W., 667 Gadallah, M.F., 301 Coles, G.A., 112 Dunea, G., 739 Garcia, N.H., 941 Colindres, R.E., 695 Dunn, M.D., 720 Gardner, J., 958 Collins, A.J., 244 Dunn, M.J., 976 Gaucher, O., 5:E21 Collins, B.H., 653 Gellens, M., 146 Comi, N., 448 Ebben, J.P., 244 Gellert, R., 157, 352 Comper, W.D., 418 Ecder, T., 427 George, A.L. Jr., $1:160 Conlon, P.J., 573 Echenagusia, A., 5:E26 Georgitis, J.W., 354 Conrad, A., 832 Edelstein, C.L., 427 Germain, M.J., 878 Constantini, E.G., 244 Eknoyan, G., $1:69 Gesualdo, L., 726 Cormier, L., 5:E21 El Asmar, B., 362 Gherardi, G., 1155 Coroneos, E., 4:E15 Elbahnasy, A.M., 720 Ghiggeri, G.M., 44 Cosio, F.G., 749 El-Ghoroury, M., 606 Ghio, L., 44 Couser, W.G., 5:E23 Elli, A., 1135 Gibney, R.T.N., 802 Covic, A., 361, 617 Endo, M., 401 Ginevri, F., 44 Covic, M., 617 Eppel, G.A., 418 Giorgi, R., 13 Covinsky, K.E., 275 Eras, J., 937 Girndt, M., 95, 611 Cruz, D., 1076 Erekul, S., 1207 Gitnick, G., 122, 832 Cueto-Manzano, A.M., 227 Ertug, A.E., 1207 Gitomer, J.J., 1:E2, 2:E5, 3:E8, 4:E14, Cushing, H., 4:E16 Ertiirk, U, 1207 5:E18, 6:E29 Cusumano, A., 408 Escriba, A., 137 Givner, L.B., 354 Cynke, E., 537 Evans, J., 904 Glassock, R.J., $1:90 Everson, S.E., 244 Gokal, R., 227 D’ Agata, E. M.C., 1083 Exner, M., 667, 1117 Gokhale, S., 319 D’ Agata, E.M.C., 64 Goldsmith, D.J.A., 361, 617 D’ Agati, V.D., 777 Fabrizi, F., 122, 832 Gonick, H.C., 963 Dagnino, M., 44 Faict, D., 112 Gonwa, T.A., $1:153 Dalleska, F., 244 Falk, R.J., 695, 1166 Gopal, H., 969 Daly, M.J., 827 Falkenhain, M.E., 749 Grady, J., 884 Daniel, L., 13 Fatica, R.A., 526 Grandaliano, G., 726 Dasgupta, M.K., 506 Fava, S., 708 Grantham, J.J., 221 Datta, S.K., 992 Federico, P., 1144 Green, K., 64 Daugirdas, J.T., 80 Feehally, J., 551 Grimm, E.M., 1:E2, 2:ES, 3:E8, Davies, S.J., 753 Ferrer, C.1., 941 4:E14, 5:E18, 6:E29 Davis, J.,$1:76 Ferreras, I., 5:E26 Group for the Water and Electrolyte De Haan, R.J., 69 Fine, A., 506 Balance Study in CAPD, 515 Deicher, R., 1117 Finkel, K.W., 1:E2, 2:E5, 3:E8, 4:E14, Grover, F.L., 1127 Deighan, C.J., 852 5:E18, 6:E29 Guardia, J.A., 5:E24 Dekker, F.W., 69 Finkelstein, F., 506 Guh, J-Y., 189 Delano, B.G., 506 Finkelstein, F.0., 638 Gupta, A., 360 Delmez, J.A., 150 Finkelstein, S.H., 638 Gusmano, R., 44 De Mattos, A.M., 333 Flis, R:S:,. 777 DeMayo, F., 362 Floege, J., 21 Haag-Weber, M., 1117 De Meer, K., 1149 Fogo, A., 1:E1, 2:E4, 3:E7, 4:E13, Haas, D.W., 64 De Nicola, L., 448 5:E17, 6:E28, 997 Haas, M., 433 Deray, G., 745 Fogo, A.B., 179, 1242 Haddad, F., 362 De Sain-van der Velden, M.G.M., Francois, M., 745 Hamm, L., S1:1 1149 Frangiosa, A., 1144 Hammermeister, K.E., 1127 De Santo, N.G., 1144 Frankel, W.L., 749 Hanaoka, M., 458 Devins, G.M., 629 Franklin, S.C., 150 Hara, M., 1186 Diaz-Buxo, J.A., 293 Freedman, B.I., 35 Hara, S., 761, 1186 Diego, J., 3:E10, 5:E24 Freemont, A.J., 227 Harada, T., 896 Diehl, L.F., 237 Frey, F.J., 624 Hashimoto, K., 889 Diemont, W.L., 845 Friedman, A., 653 Hasnain, M., 739 Disney, A.P.S., 157, 352 Frimat, L., 5:E21 Hassan, H., 146 Dixit, V., 122, 832 Puse,:207 Hateboer, N., 753 Doe, N., 4:E15 Fuiano, G., 448 Hattersley, A.T., 708 Doesburg, W.H., 845 Fujimoto, K., 863 Haubitz, M., 21 AUTHOR INDEX Hauk, M., 105 Jaradat, M., 4:E16 Koomans, H.A., 202 Hayano, S., 323 Jeffery, S., 211 Kopp, J.B., 408, 1166 Hayashi, T., 194, 250 Jennette, J.C., 1166 Kopple, J.D., S1:1, $1:93 Hayek, G., 362 Johnson, A.M., 427 Korbet, S.M., 506, 904 Hegde, A., 1039 Johnson, C.A., | Kovarik, J., 667 Heidenheim, P., 506 Jones, C.A., 80 Kravet, S., 173 Heidland, A., 347 Jones, C.H., 827 Krediet, R.T., 69, 819 Helderman, H., 154 Jones, E., 157, 352 Krepinsky, J., 500 Helderman, J.H., 1242 Jones, S., 112 Krisher, J., 35 Helmandollar, A.W., 266 Jost, M-C., 537 Krisper, P., 529 Henderson, L.W., $1:106 Joy, M.S., 695 Kshirsagar, A.V., 695 Henderson, W.G., 1127 Julian, B.A., 555 Kubo, H., 465 Hermann, J.A., 282 Juncos, L.I., 941 Kuhlmann, M.K., 105 Hernandez, E., 141 Kulik, W., 1149 Herrero, J.C., 137 Kumano, K., 515 Herzenberg, A.M., 5:E25 Kalra, P.A., 573 Kundu, G., 362 Herzog, C.A., 1217 Kambham, N., 777 Kuo, H-T., 189 Kaneda, H., 863 Hewan-lowe, K., 1:53 Kurtzman, N.A., 327 Kang, S-H., 923 Hewan-Lowe, K., 783 Kusaka, M., 221 Kanno, Y., 408 Hickman, R., 477 Kutsogiannis, D.J., 802 Karatan, O., 1207 Hilbrands, L.B., 2:E6 Kuzuhara, K., 761 Karsou, S.A., 980 Hirsch, D.J., 588 Kyriazis, J., 1096 Kasahara, M., 221 Hisada, Y., 169 Kasahara, Y., 863 Ho, K.K.L., 392 Kasai, K., 465 Lafayette, R., 166 Hogan, S.L., 695 Katoh, N., 465 Lai, K.B., 644 Hollander, W.M., 884 Holley, J.L., 1061 Katori, H., 761, 1186 Lai, K.N., 644 Katz, J., 629 Lai, Y-H., 189 Holmes, C.J., 112 Kaul, H., 95, 611 Lai Mac-Moune, F., 392 Holzer, H., 529 Kawaguchi, Y., 465, 515, 1072 Lam, C.W.K., 644 Hori, M., 194, 250, 713 Kawakatsu, H., 5:E22 Lan, H.Y., 418 Horl, W.H., 130, 667, 1117 Kawamura, T., 889, 896 Lan, J-L., 52 Horn, K., 4:E15 Kawasaki, C., 323 Laski, M.E., 1224 Horn, R.G., 1242 Kaysen, G., S1:1 Lazarou, L.P., 753 Hosoya, T., 465 Kaysen, G.A., 469, 1149 Lazarus, J.M., 293, 598 Hovick, E.T., 1052 Keane, W.F., $1:97 Le, L., 319 Hsu, H-C., 313 Kennefick, T.M., 923 LeBrun, C.J., 237 Hubert, J., 5:E21 Kessler, M., 5:E21 Lederer, E., 1238 Hull, C.M., 5:E23 Keur, I., 819 Leitner, G., 529 Hutchison, A.J., 227 Keven, K., 1207 Lemmens, W.A.J.G., 845 Hwang, S-J., 189 Khairullah, Q., 606 Lengler, S., 95 Khan, S., 1039 Leung, C.B., 392 Ichikawa, I., 5:Iviii—Ix Kiaii, M., 5:E25 Leung, J.C.K., 644 Imai, E., 194, 250, 713 Kimmel, P.L., $1:132, 1221 Leunissen, K.M.L., 5:E19 Imai, H., 3:E9, 3:E11 Kirschbaum, B., 1068 Levey, A.S1:., Si:117 Imai, T., 761 Kitabayashi, A., 3:E11 Levi, M., 365 Ingram, A.J., 500 Kitagawa, S., 6:E31 Levin, N.W., S1:69 Inoue, S., 761 Kitamura, A., 761, 1186 Levine, R.A., 469 Iodice, C., 448 Klassen, G.A., 588 Lew, N.L., 293, 598 Ishikawa, I., 6:E31, 216, 1072 Kliger, A.S., 638 Lewis, E.J., 904 Ishikawa, Y., 216 Knostman, J.D., 5:E23 Lewis, J.B., 154 Ishiwari, K., 5:E22 Kobayashi, Y., 896 Li, C.S., 660 Iskander, S.S., 354 Kodama, T., 3:E9 Li, F.K., 644 Itoh-Ihara, T., 889 Koenig, K.G., 266 Li, P.K.T., 392 Izumi, M., 713 Kohl, J., 21 Li, Z., 598 Izzedine, H., 745 Kohler, H., 95, 105, 611 Lian, J-D., 52 Koizumi, S., 863 Lien, Y-H.H., 539 Jaar, B.G., 282 Kojima, K., 1175 Lin, C-H., 313 Jaber, B.L., 980 Komatsu, H., 5:E22 Litalien, C., 29 Jager, K.J., 69 Komatsuda, A., 3:E9, 3:E11 Liu, J.S., 216 Janigan, D.T., 588 Konel, S., 227 Lépez-Baena, J.A., 5:E26 Janssen, U., 21 Kooman, J.P., 5:E19 Lorentz, W.B., 354 1254 AUTHOR INDEX Losito, A., 211 Molony, D.A., 1:E2, 2:E5, 3:E8, Oberley, E.T., $1:141 Lowenfels, A.B., 157, 352 4:E14, 5:E18, 6:E29 O’Brien, M., 1127 Lowrie, E.G., 293, 598 Monno, R., 726 Oderinde, A., 1:E3 Lugon, J.R., 839 Montagnino, G., 1135 Ogiso, N., 221 Lui, S.F., 392 Moore, J. Jr., 1039 Ohi, H., 401 Moore, K.D., 796 Ohsawa, I., 401 Moore, L.W., $1:19 Ohta, K., 863 Ma, J.Z., 244 Morales, E., 137, 141 Ohtani, H., 3:E9, Ell Maccario, M., 1135 Moriggi, M., 381 Okada, N., 194, 250 McClellan, W.M., 35 Moritz, T.E., 1127 Olson, J.L., 557, 674 McConnell, M., 852 Morrison, L., 606 Olyaei, A.J., 333 McCredie, M., 157, 352 Morton, A.R., 306 O’Neill, W.C., 978, 1021 McCusker, F.X., 506 Mosconi, L.M., 381 Ono, T., 889 MacDonald, A.S., 588 Moseley, A., 112 Orhan, D., 1207 McDougall, E.M., 720 Mount, D.B., 1083 O’Riordan, E., 573 Mackenzie, R.K., 112 Mouratoff, J.G., 557 Ortel, T.L., 796 McKinley, M., $1:19 Mousa, M., 122 Orth, S.R., 767 McMurray, S.D., 506 Mueller, B.A., 310 Ortufio, T., 137 McNeil, B.J., 1044 Muiiio, J.C., 941 O’ Shea, M.H., 878 Madaio, M.P., 992 MMaaddih-aJne,b arKa.,K .,S .,1 231622 MMuulkhheerrnj,e e,J .GA..,B .8,7 83 62 OOtuasgeiprih,, MR..,, 3892 3 Maeda, K., 1072 Munir, I., 950 Ovuworie, C., 173 Magil, A.B., 5:E25 Murer, L., 44 Oyama, A., 889 Mahnensmith, R.L., 1076 Musv, E., 889 OOyyaammaa,, TY..T,. ,3 :9E2113 Maisonneuve, P., 157, 352 Myll, J., 482 Mamouna, A., 1096 Mantadilok, V., 469 Nadasdy, T., 1193 Pacheco, D., 5:E26 Manton, W.I., 963 Nagahama, K., 1186 Packard, C.J., 852 Mariscalco, M.M., 29 Nagao, S., 221 Painter, P., 482 Markowitz, G.S., 777 Nagaraj, S.K., 354 Parente, B., 211 Martin, P., 122, 832 Pauesakon, P., 1242 Nagase, M., 1175 Martin, S. R., 1089 Nagatoya, K., 713 Paul, S.M., 482 Maschio, G., 4:liv—lvi Nagy, M., 1104 Paulson, W.D., 973, 1089 Mason, N.A., | Paun, M., 477 Nakai, S., 1072 Matos, J.P.S., 839 Peces, R., 954 Nakamoto, Y., 3:E11 Matsuda, J., 221 Pegoraro, A.A., 739 Nakamura, H., 713 Matsui, K., 1175 Pellissier, J-F., 13 Nakanishi, I., 194 Matsuo, T., 458 Peracha, W., 739 Nakano, H., 465 Matsushita, M., 401 Perazella, M.A., 937, 1076 Nakayama, M., 465 Matsushita, Y., 761, 1186 Pereira, B.J.G., 980 Nakazawa, T., 6:E31, 216 Mawer, B., 227 Perfumo, F., 44 Nash, S.V., 878 MaWhinney, S., 1127 Perna, A., 1155 Nassar, G., 1193 Mayers, I., 802 Peterson, D.D., 1052 Mazza, G., 448 Neilson, E.G., S$1:160 Pfister, M., 624 Meehan, S.M., 433 Nergizoglu, G., 1207 Phillips, C., 4:E16 Meissner, M., 477 Neumayer, H-H., 3:E12 Piaggio, G., 44 Melissant, C. F., 1149 Newstead, C.G., 827 Pieper, D., 606 Mercadal, L., 745 Nieto, F.J., 812 Pintar, T.J., 653 Merkus, M.P., 69 Nikolic-Paterson, D.J., 418 Piraino, B., 1104 Mestecky, J., 555 Nimura, T., 3:E11 Pirsch, J.D., 653 Meuleman, E.J.H., 845 Nishi, R., 323 Plante, C.L., $1:45 Meyer, T.W., 674 Nishida, M., 5:E22 Plett, C., 477 Miki, K., 3:E9 Noble, N.A., 773 Pobes, A., 954 Miller, J., 3:E10 Nogueira, M., 4:E15 Poffenbarger, T., 681 Miller, S.B., 150 Nomura, M., 458 Polito, A., 832 Milutinovic, J., 950 Normand, S.T., 1044 Pollastro, R.M., 1144 Miura, A.B., 3:E9, E11 Novak, J., 555 Polo, J.R., 5:E26 Moe, S., 4:E16 Nudo, S.A., 796 Ponticelli, C., 1135 Mohler, J.H., 533 Niiesch, R., 537 Port, F.K., 80, 1226 Moles, K., 301 Nylander, W., 997 Portis, A.J., 720 Molino, D., 1144 Nzerue, C.M., 1:E3, 783 Portman, R., 681 AUTHOR INDEX Postler, G., 871 Sawada, T., 5:E22 Strandness, D.E. Jr., 477 Powe, N.R., 282 Saxena, R., 749 Sugaya, T., 169 Powers, K.M., 266 Schadeli, F., 624 Sugiura, T., 713 Prag, K.A., 310 Schaffner, W., 64, 1083 Suri, D.L., 674 Praga, M., 137, 141 Schena, F. P., 726 Suzuki, A., 194, 250 Pressman, M.R., 1052 Schenk, P., 130 Suzuki, S., 896 Proulx, F., 29 Schievink, W.I., 40 Suzuki, Y., 896 Provenzano, R., 606 Schneditz, D., 529 Symmans, P., 1212 Provoost, A.P., 202 Schotschel, R., 3:E12 Szeto, C.C., 392 Pu, K., 112 Schreiner, G.E., $1:37 Schrier, R.W., 427 Tagami, T., 761, 1186 Quan, S., 832 Schulman, G., 64 Takagawa, R., 761 Schwartz, M.M., 904 Takahashi, H., 221 Rabb, H., 871 Scott, K., 539 Takahashi, Y., 458 Rabelink, T.J., 1149 Scott, M.K., 310 Takazoe, K., 418 Racusen, L., 173 Seco, M., 954 Takemoto, F., 761, 1186 Rahman, M., 257 Sedmak, D.D., 749 Tamai, M., 5:E22 Raj, D.S.C., 365 Sehgal, A.R., 257, 275, S$1:148 Tanawattanacharoen, S., 1166 Rajaraman, S., 319, 884 SeidmanA,. , 1039 Tang, N.L.S., 392 Ram, S.J., 1089 Seidman, E., 29 Tarantino, A., 1135 Ranginwala, N., 739 Seki, H., 863 Tayeb, J.S., 606 Ranieri, E., 726 Seno, A., 863 Tenenbein, M., 958 Ravine, D., 753 Sepe, J., 1144 Tenney, F., 5:E20 Regalado, M., 687 Sester, M., 95, 611 Te Strake, L., 1212 Regele, H., 667 Sester, U., 95, 611 Thayer, V., 1083 Reichlin, M., 904 Sethi, G. K., 1127 Thompson, M.M., 923 Rembold, S.M., 839 Shahinian, V., 884 Tiesenhausen, K., 529 Remuzzi, A., 381 Shalhav, A.L., 720 To, K.F., 392 Remuzzi, G., 381, 1155 Shappell, H.W., 997 Togawa, M., 194, 250 Renoult, E., 5:E21 Shappell, S., 4:E15 Tokumoto, J., 557 Revelo, M.P., 1242 Shaykh, M., 739 Toma, T., 863 Riegel, W., 105 Shek, C.C., 660 Tomana, M., 555 Riley, L.J. Jr., 783 Sherrard, D.J., 969 Tomino, Y., 896 Ritz, E., 767 Shigematsu, T., 465 Tomlanovich, S.J., 674 Rodriguez, M., 954 Shoji, T., 194, 250 Tomosugi, N., 6:E31, 216 Rodriguez-Iturbe, B., 1:xlvi-xlviii Shrivastav, S., 408 Topley, N., 112 Rohde, R.D., 904 Shroyer, A.L., 1127 Toral, C., 3:E10 Romero, M., 941 Shu, K-H., 52 Torres, V.E., 40, 547, 930 Rosenkranz, A.R., 130 Silva, L. R., 1044 Tostivint, I., 745 Roth, D., 3:E10 Silver, M.R., 275 Traindl, O., 130 Rothenberg, S., 963 Simckes, A.M., 1111 Truong, L., 1193 Rothstein, M., 720 Simon, D., 1076 Truong, L.D., 4:E15 Rubin, J.M., 526 Singer, M.A., 306 Tsai, J-C., 189 Ruggenenti, P., 381, 1155 Singh, A.K., 739 Tsai, J-H., 189 Sklar, A.H., 969 Tsubakihara, Y., 194, 2 Sadler, J.H., $1:141 Smith, M.C., 257 Tsukamoto, Y., 458 Saemann, M.D., 667 Smoyer, W.E., 958 Tulunay, O., 1207 Saingra, Y., 13 Soleimani, M., 871 Turgeon, J.P., 29 Saito, I., 465 Sollinger, H.W., 653 Saito, Y., 216 Sorof, J.M., 681 Ubara, Y., 761, 1186 Sakai, S., 465 Soucie, J.M., 35 Ucci, A.A. Jr., 878 Sakamoto, K., 6:E31 Sowinski, K.M., 310 Uehlinger, D.E., 624 Sakarcan, A., 5:E20 Spargo, B.H., 433 Uekihara, S., 323 Sambuelli, R.H., 941 Spitali, L., 1144 Uflacker, R., 950 Sands, J.J., 796 Sposito, M., 812 Sangalli, F., 381 Stamatiadis, D., 1096 Vamvakas, S., 347 Sankarasubbaiyan, S., 1061 Steinberg, E.P., $1:69 VanBuren, D., 997 Sano, K., 465 Steinman, T.I., 770 Van der Merwe, W., 1212 Sarnak, M.L., $1:117 Stellato, D., 1144 Van der Sande, F.M., 5:E19 Saruta, T., 458 Stewart, J.H., 157, 352 Vanherweghem, J-L., 330 Sasayama, S., 889 Stigant, C.E., 58 Van Olden, R.W., 819 1256 SUBJECT INDEX Vega, D., 5:E26 Weitzel, W., 526 Yamamoto, H., 465 Veis, J.H., 1039 Welbourne, T.C., 365 Yang, C-S., 313 Vendramin, G., 381 Welch, P.G., 237 Yang, S., 687 Ventura, J.E., 812 Wesseling, K.H., 819 Yashiro, M., 889 Verseput, G.H., 202 Wesson, D.E.., 3:lii—liv, 687 Yazigi, A., 362 Vijayan, A., 150 Westerhof, N., 819 Yeun, J.Y., 469 VillaNueva, C.B., 1127 Wetzels, J.F.M., 2:E6 Yokata, M., 1186 Vinson, S., 122 Whiteside, C., 629 Yokota, M., 761 Vivera, M., 58 Wijdicks, E.F.M., 40 Yokoyama, H., 863 Volcy, J., 1:E3 Wilkowski, M.J., 266 Yoshida, H., 896 Volmar, K., 173 Williams, J.D., 112 Yoshida, I., 930 Vruggink, P.A., 845 Wit, E-J.C., 433 Yuan, C.M., 237 Wolfe, R.A., 80, 157, 352 Yum, M-N., 4:E16 Wada, T., 863 Wolfl, G., 130 Yurik, T., 6:E31 Waiser, J., 3:E12 Woltmann, D., 526 Wakui, H., 3:E9 Wong, K.M., 660 Wang, A. Y.M., 392 Wong, T.Y.H., 392 Zabetakis, P.M., 506 Wang, Z., 871 Work, J., 1089 Zaltzman, J.S., 58 Warady, B.A., 1111 Wu, M-J., 52 Zapezynski, M., 1089 Ward, J., 362 Wuerth, D.B., 638 Zhang, H., 293 Ward, M.M., 915 Wyckoff, S.J., $1:49 Zhang, Z., 362 Ward, R. A., 89 Zheng, F., 362 Watkins, P.J., 708 Yachie, A., 863 Zimmerli, W., 537 Watschinger, B., 667 Yamada, A., 761, 1186 Zimmerman, S.W., 506 Weening, J.J., 202 Yamaguchi, A., 3:E11 Zlabinger, G.J., 667 Weidner, M., 1242 Yamaguchi, T., 221 Zwirner, J., 21 SUBJECT INDEX Articles under the rubric Of Nephrology and Nephrologists are referred to by journal number, a colon and page numbers. Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number. Page references to Supplement 1 (April 2000) and Supplement 2 (June 2000) are preceded, respectively, by S1: and S82:. Abstracts, from 9th Annual Clinical Nephrology Meeting, Acute illness, during maintenance dialysis 4:A1-A29 energy intake and, $2:51-53 ACE gene polymorphisms. See Angiotensin-converting en- protein intake and, S2:51-53 zyme gene polymorphisms Acute phase response activation, in IgA nephropathy, 21-28 Acute renal failure (ARF) ACEi. See Angiotensin-converting enzyme inhibitors cocaine-associated, 783-795 Acetic dialysate, dialysis dose and, 493-499 COX-2 inhibitor associated, 937-940 Acid-base status diagnosis, Doppler ultrasound for, 713-719 cocaine-induced imbalance, 789 etiology/outcome in elderly, 433-447 management guidelines with interstitial nephritis in AIDS, 557-561 adult, $2:38-39 noni juice-induced hyperkalemia and, 310-311 pediatric, $2:107—108 normeperidine neurotoxicity treatment and, 146-149 Acidemia, treatment, $2: 38-39 outcome after cardiac valve surgery and, 1127-1134 outcome variables, intermittent hemodialysis and, 980- Acidosis, metabolic. See Metabolic acidosis 991 Activated charcoal, for diethylene glycol poisoning, 958— pediatric, peritoneal dialysis catheter choice for, 1111- 962 1116 Active transport inhibitor, for lead, in uremic plasma, 963- potassium excretion impairment in, 871-877 968 renal bopsy, 448-457 SUBJECT INDEX secondary to hematuria and tubular necrosi Amyloidosis ultrasonography, 1021-1039 remission after Castleman’s disease removal, 1207-1211 Acute tubular necrosis (ATN) secondary differential diagnosis, Doppler ultrasound for, 713—719 in fibrillary glomerulonephritis, 173-177 etiology/outcome, in elderly, 433-447 in giant-cell arteritis, 137-140 ultrasonography, 1021-1039 in polymyalgia rheumatica, 137-140 Adequacy ANCA (antineutrophil cytoplasmic antibody), in anti-GBM- impact of intermittent hemodialysis variables on, 980-991 associated glomerulonephritis, 954-957 increased dialysate flow rate and, 05-111 Anemia Netherlands Cooperative Study on, 69-79 in ESRD peritoneal dialysis iron therapy for, 1-12 multicenter cross-sectional study of, 515—525 with sleep disorders, mortality prediction for, 1052-1061 in U.S. vs. Canada, 506-514 exacerbation in CRF, ACE inhibitors and, 1076-1082 with two parallel dialyzers, 266-274 Angiitis, MPO-ANCA-associated, 889-895 Adjusted edema-free body weight, maintenance dialysis, Angiotensin, in renal fibrosis, maximal reduction of, 773-776 $2:36-37 Angiotensin-converting enzyme gene polymorphisms ADPKD. See Autosomal dominant polycystic kidney dis- DD, RVD survival and, 211-215 ease insertion/deletion, IgA nephropathy progression and, 896— Advanced glycation end products (AGEs), renal effects, 903 365-380 Angiotensin-converting enzyme inhibitors Age/aging antiproteinuric effect, 381-391 blood pressure in hemodialysis and, 257-265 in chronic allograft nephropathy, 154-156 AIDS interstitial nephritis, with acute renal failure, 557—S61 in diabetic and nondiabetic chronic renal disease, 695— Air pollution, MPO-ANCA-associated angitis/nephritis and, 707 889-895 for hypertensive ADPKD patients, 427-432 Albumin, serum kidney disease progression and, 1155-1165 ACE inhibition in diabetic vs. nondiabetic chronic renal for prevention of terminal renal failure in albuminuria, disease and, 695-707 202-210 low levels, CRP and, 469-476 for renal transplant recipients, 58-63 measurement methods, S2:66 rHuEPO requirements in hemodialysis and, 1076-1082 mortality prediction in ESRD with sleep disorders and, Angiotensin II 1052-1061 in immune-mediated renal injury, 166—172 nutritional status in maintenance dialysis and, $2:20-21 in progressive glomerulosclerosis, 179-188 outcome prediction in chronic dialysis, 69-79 Angiotensin II antagonists processing for chronic allograft nephropathy, 154-156 in anti-glomerular basement membrane glomerulone- for renal transplant recipients, 58-63 phritis, 418-426 Angiotensin receptors, new research on, 5: i-iii in anti-Thy1 nephritis, 418-426 Anion gap increase, in metabolic acidosis of hemodialysis, Albuminuria 1068-1072 absence, glomerular filtration rate and, 1144-1148 Anthropometry methods. See also specific anthropometric diagnosis, fluorescent dye method vs. radioimmunoassay methods for, 739-744 nutritional status in maintenance dialysis and, $2:32—33 in progressive renal disease, S1: 97-105 performance, S2:76-85 in terminal renal failure, prevention of, 202-210 Antibiotics, for chronic hemodialysis, 64-68 total protein excretion and, 418-426 Anticoagulation Alcohol dehydrogenase inhibitor, for diethylene glycol poi- heparin vs. rTPA, for Quinton Permcath priming, 130-136 soning, 958-962 population pharmacodynamic model for, 89-94 Alcoholism prevalence, in dialysis patients, 1039-1043 regional citrate, in CVVHDF, 802-811 Allograft dysfunction Anti-glomerular basement membrane antibodies, glomerulo- in adult male, 997-1001 nephritis-associated with, 954-957 vein thrombosis, surgical thrombectomy of, 5:E21 Anti-glomerular basement membrane disease Allograft failure, with systemic lupus erythematosus, 1242— glomerulonephritis, albumin processing in, 418-426 1247 pathogenesis, All and, 166-172 Allograft nephropathy, angiotensin-converting enzyme in- Antihypertensive therapy hibitors in, 154-156 for hypertensive ADPKD patients, 427-432 Allopurinol, for familial microscopic hematuria, 141—i45 for nondiabetic nephropathy, 4: liv—Ivi Alternative medicine Antineutrophil cytoplasmic antibody (ANCA), in anti-GBM- Chinese herbal nephropathy and, 330-331 associated glomerulonephritis, 954-957 noni juice-induced hyperkalemia, 310-311 Antioxidant, effects on PKD murine model, 221-226 Aminoguanidine, inhibition of AGEs, 373-374 Antiphospholipid antibodies, vascular access thrombosis Amlodipine, for hypertensive ADPKD patients, 427-432 and, 796-31 1258 SUBJECT INDEX Anti-Thy! nephritis, albumin processing in, 418-426 idiopathic focal segmental glomerulosclerosis in, 878— ANZDATA registry, cross-cultural comparison of renal dis- 883 ease classifications, 157-165 mortality risk with dialysis dose, body size and, 80-88 Arachnoid cysts, subdural hematoma in ADPKD and, 40-43 Blood flow, in curved-tip vs. standard dialysis catheters, Area under concentration curve, for tacrolimus monitoring 624-628 of transplant recipients, 660-666 Blood pressure ARF. See Acute renal failure in chronic hemodialysis, 257—265 L-Arginine, effects on polycystic rat model, 930-936 dialysate calcium level and, 1096-1103 Aristolochic acid, fibrosing interstitial nephritis from, 313- seasonal variations, 812-818 318 and ultrafiltration, 819-826 Arterial compliance, dialysate calcium level in hemodialysis circadian variation in rHuEPO therapy for CRF and, and, 1096-1103 250-256 Arteriole calcification, in chronic renal failure, 588-597 normal, glomerular filtration rate and, 1144-1148 Arteriopathic renal diseases, cross-cultural classification com- post-transplantation changes in children, 681-686 parisons, 162 predictive accuracy for graft thrombosis, 1089-1095 Arteriovenous fistula, microembolic signals in, 526-528 in renal insufficiency, smoking-related progression of, Arteriovenous graft, microembolic signals in, 526-528 687-694 AT la receptor knockout, immune-mediated renal injury and, renal mass reduction, adaptation in polycystic rat, 923- 166-172 929 Atherosclerotic renovascular disease (ARVD), epidemiology/ Blood vessel prosthesis blood flow decrease, in graft throm- clinical manifestations, 573-587 bosis prediction, 1089-1095 AT II antagonists. See Angiotensin II antagonists Blood volume, in hemodialysis and ultrafiltration, 819-826 Autosomal dominant polycystic kidney disease (ADPKD) BMI. See Body mass index age of hemodialysis induction, gender differences in, Body fat, estimation, $2:81—82 1072-1075 Body mass index (BMI) chronic subdural hematoma in, 40-43 calculation, $2:77 ESRD, laparoscopic nephrectomy for, 720-725 glomerular filtration rate in normotension and, 1144-1148 hypertension, antihypertensive therapy for, 427-432 hemodialysis dose, mortality and, 80-88 with Marfan syndrome in kindred, 753-760 urea reduction ratio, urea product and, 598-605 pain management in, 770-772 Body size, hemodialysis dose, mortality and, 80-88 progression, hypertension/proteinuria and, 547—550 Body weight racial variation in, 35-39 renal mass reduction for, 923-929 excessive. See Obesity Azotemia glomerular filtration rate in normotension and, 1144-1148 interdialytic gain, blood pressure in hemodialysis and, differential diagnosis, Doppler ultrasound for, 713-719 257-265 neutrophil 8,-microglobulin and lactoferrin content in, measurements 1117-1126 by age, $2:130-131 Basic fibroblast growth factor, during peritonitis CAPD, methods for, $2:124 644-652 standard, percentage of, S2:76-77 BCG (bromcresol green assay), S2:66 standing, measurement method, $2:124 Berger’s disease, histologic features, survival and, 392-400 Bone densitometry, of long-term renal transplant recipients, 227-236 BIA (bioelectrical impedance analysis), $2:86 Bicarbonate, serum Bone histomorphometry low, treatment of, $2: 38-39 of long-term renal transplant recipients, 227-236 in maintenance dialysis 22-oxacalcitriol effects on, 458-464 measurement, 39, $2: 38 Bone loss, renal transplant-associated, 1,25-dihydroxyvita- pediatric guidelines, $2:107—108 min D; and calcium carbonate effects on, 227-236 Bicarbonate-buffered peritoneal dialysis fluid, ex vivo peri- Bovine thrombin antibodies, vascular access thrombosis toneal macrophage function and, 112-121 and, 796-801 Bicarbonate dialysate concentration, metabolic acidosis and, Bowman’s capsule volume, digital reconstruction in glomeru- 1224-1225 locystic kidney disease, 216-220 Biocompatibility Brachiocephalic vein occlusion, secondary unilateral breast of bicarbonate-buffered dialysis fluids, 112-121 enlargement from, E:26 of dialyzer membranes, outcome and, 980-99 | Breast cancer screening, failure of, 327-329 of vitamin E-coated dialyzer membranes, 95-104 Bromcresol green assay (BCG), S2:66 Bioelectrical impedance analysis (BIA), S2:86 Biological scaling, Kt/V and, 306-309 Calcifications Blacks in chronic renal failure, 588-597 ADPKD in, 35-39 peritoneal, after long-term CAPD, 761-766 blood pressure in hemodialysis, 257-265 Calciphylaxis, in chronic renal failure, 588-597 SUBJECT INDEX 1259 Calcitriol, pulsed-dose, for secondary hyperparathyroidism, Cell proliferation, in polycystic kidney disease, lovastatin 465-468 and, 221-226 Calcium Channel inducing factor (CHIF), in acute renal failure, in dialysate, arterial compliance in hemodialysis and, 871-877 1096-1103 Charcoal hemoperfusion, for phenytoin overdosage, 323- posthemofiltration levels , for regional citrate anticoagula- 326 tion, 802-811 Children Calcium carbonate, renal transplant-associated bone loss acid-base status management guidelines, $2:107—108 and, 227-236 diethylene glycol poisoning in, 958-962 Calcium channel blockers, for hypertensive ADPKD pa- with hemolytic uremic syndrome, TGFB-1 and lympho- tients, 427-432 kines in, 29-34 Calcium oxalate, in familial microscopic hematuria urine hypertensive emergencies, nicardipine for, 5:E20 sediment, 141-145 kidney transplantation, abnormal 24-hour blood pressure Cancer patterns, 681-686 dialysis-associated, incidence/spectrum of, 347-353 maintenance dialysis. See K/KOQI Nutrition Clinical Prac- screening tice Guidelines, pediatric breast, failure of, 327-329 peritoneal dialysis, catheter choice for, 1111-1116 in end-stage renal disease, life expectancy benefits of, renal effects of cocaine exposure, 783-795 237-243 Chinese herb nephropathy (CHN) incidence of, 330-331 CAPD. See Continuous ambulatory peritoneal dialysis Cardiac compromise, improving hemodynamic stability dur- progressive fibrosing interstitial nephritis in, 313-318 ing hemodialysis, 5:E19 Cholesterol Cardiac oxygen supply/demand, in hemodialysis and ultrafil- nutritional status in maintenance dialysis and, $2:25—26 tration, 819-826 in PKD model, probucol effects on, 221-226 Chronic interstitial nephritis, incidence, 878-883 Cardiac valve surgery, mild renal failure outcome after, 1127-1134 Chronic renal failure, progression in hypertension, augmen- tation by smoking, 687-694 Cardiopulmonary manifestations, of Henoch-Schonlein pur- Chronic renal failure (CRF). See also End-stage renal dis- pura, 319-322 ease Cardiopulmonary vasculitis, in Henoch-Sch6nlein purpura, ADPKD-associated, racial variation in, 35-39 319-322 anemia exacerbation, ACE inhibitors and, 1076-1082 Cardiovascular disease calcified arterioles and subcutaneous infarcts in, 588—597 chronic renal disease and, $1:117-131 cocaine in, 790-791 comorbidity, blood pressure in hemodialysis and, 259, delayed by ACE inhibition, 202-210 261, 262-263 Dialysis Outcomes Quality Initiative, $1:69-75 mortality prediction in hemodialysis, CRP and, 469-476 EPO therapy, hematocrit target for, 250-256 risk hemodialysis, diabetic muscle infarction and, 1212-1216 proteinuria and, $i1:97-105 in juvenile nephronophthisis, 44-51 small dense LDL and, 852-862 nondialyzed L-Carnitine, for maintenance dialysis dietary energy intake for, $2:60-61 adults, $2:54—55 dietary protein intake for, S2:58-59 children, S2:88—92 intensive nutritional counseling for, S2:62-63 Case-control design study, of prolonged hypoglycemia in nutritional measures for, $2:56—57 ESRD, 500-505 prediction, in IgA nephropathy, 13-20 Castleman’s disease, localized removal , nephrotic syn- progression, aminoguanidine prevention of, 365-380 drome remission after, 1207-1211 protein-energy malnutrition causes, $2:9 Catheters proteinuria and, $1:97—105 hemodialysis renal biopsy, 448-457 blood flow in curved-tip vs. standard, 624-628 survival after acute myocardial infarction, 1044-1051 central venous soft cuffed implantable, priming of, ultrasonography, 1021-1039 130-136 Cigarette smoking. See Smoking facility specific standardized ratio calculation, 275-281 Circadian rhythm, blood pressure variation, rHuEPO therapy peritoneal dialysis for CRF and, 250-256 pediatric, 1111-1116 Citrate anticoagulation, regional, in CVVHDF, 802-811 repositioning, Fogarty catheter manipulation for, 301— Citrate dialysate, dialysis dose and, 493-499 305 Classification C4d, antibody-mediated graft injury in spousal-donor kid- of Haas, prognostic value of, 13-20 ney transplantation, 667-673 of primary renal diseases, world-wide differences in, 157- CD4 lymphocytes, in renal disease in HIV-transgenic mice, 165 408-417 Clinical performance measures, Dialysis Outcomes Quality Celecoxib, nephrotoxicity, 937-940 Initiative, S1:69-75 1260 SUBJECT INDEX Clinical practice guidelines, Dialysis Outcomes Quality Ini- Creatinine urine/serum ratio, in differentiation of prerenal tiative, $1:69-75 azotemia from ATN, 713-719 Coagulation. See also Anticoagulation Crescentic giomerulonephritis, tissue factor, PAI-1 and throm- in crescentic glomerulonephritis, 726-738 bin receptor expression in, 726-738 Cocaine abuse, kidney and, 783-795 Crescents Cohort study, of survival after myocardial infarction in IgA nephropathy prognosis and, 13—20 ESRD, 1044-1051 in pauci-immune necrotizing lupus nephritis, 1193-1206 Comorbidity Cross-cultural comparison, of primary renal disease classifi- in hemodialysis, 2:xlvi—xiviti cations, 157-165 reuse-associate mortality and, 244-249 Cross-infection in chronic hemodialysis, risk factors for, Complement activation, in Henoch-Schénlein purpura nephri- 1083-1089 tis, 401-407 CRP. See C-reactive protein Complement C3, in IgA nephropathy, 21-28 Cryoglobulinemia glomerulopathy, splenectomy and, 1186— Complex traits, in kidney disease, $1:160—169 1192 Compliance. See also Noncompliance Cuprammonium membrane biocompatibility, serum albu- alcoholism and, 1039-1043 min and, 606-610 blood pressure and, 257-265 CVVHDF (continuous venovenous hemodiafiltration), re- with dialysis exchanges in peritoneal dialysis, 1104-1110 gional citrate anticoagulation in, 802-811 Congenital diseases, cross-cultural classification compari- Cyclooxygenase-2, renal cell adaptation to hypertonicity sons, 157-165 and, 6:xlvii-l Congestive heart failure Cyclooxygenase-2 enzyme inhibitors, nephrotoxicity, 937- atherosclerotic renovascular disease and, 573-587 940 comorbidity, blood pressure in hemodialysis and, 257- Cyclophosphamide, long-term, for post-transplant MPGN 265 prophylaxis, 539-542 Continuous ambulatory peritoneal dialysis (CAPD) Cyclosporine catheter migration, Fogarty catheter manipulation for, long-term, for post-transplant MPGN prophylaxis, 539- 301-305 542 long-term, ectopic intestinal wall calcification in, 761- nephrotoxicity of, 333-346 766 for transplant patients, long-term results of, 1135-1143 noncompliance, in US vs. Canada, 506-514 Cyroglobulinemia, subclinical, in HD and KT patients, 52-57 noncompliance pattern with dialysis exchanges, 1104— Cytokines. See also specific cytokines 1110 induction for peritonitis, cytokine profile changes in, 644-652 through dialyzer membranes, in ESRD, 611-616 sexual dysfunction after, 845-851 vitamin E-coated dialyzer membranes and, 95—104 Continuous venovenous hemodiafiltration (CVVHDF), re- profile changes during peritonitis CAPD, 644-652 gional citrate anticoagulation in, 802-811 Cook catheters, for pediatric peritoneal dialysis, 1111-1116 1,25(OH),D; derivatives, for secondary hyperparathyroid- Coronary artery disease, risk, with hyperphosphatemia and ism in CAPD, 761-766 hyperparathyroidism in dialysis, 1226—1237 DEG (diethylene glycol), childhood poisoning, treatment of, Corticosteroids, for diffuse proliferative [IgA nephropathy, 958-962 194-201 Depression, in end-stage renal disease, $1:132-140 Cox2 selective inhibitors, nephrotoxicity, 976-977 Dextran fractional clearance, ACE inhibition and, 381-391 Clq nephropathy, spontaneous improvement, 5:E22 Diabetes mellitus C-reactive protein (CRP) in IgA nephropathy, 21-28 chronic renal disease, ACEi effects in, 695-707 mortality prediction in hemodialysis and, 469-476 complications. See also Diabetic nephropathy Creatinine advanced glycation end products and, 369-370 in hypertensive-associated renal disease, smoking and, muscle infarction in dialysis patients, 1212-1216 687-694 cross-cultural classification comparisons, 157—165 mild renal failure outcome after cardiac valve surgery and, end-stage renal disease, prolonged sulfonylurea-induced 1127-1134 hypoglycemia in, 500-505 nutritional status in maintenance dialysis and, $2:23-24 hemodialysis, septicemia in, 282-292 Creatinine clearance with proteinuria, cardiovascular morbidity/mortality and, in Japanese peritoneal dialysis patients, 515-525 $1:97-105 long-term cyclosporine monotherapy in transplant pa- type 2 tients and, 1135-1143 familial clustering of proteinuria in, 708-712 in overweight normotensive humans, 1144-1148 progressive renal failure with nephrotic syndrome in, Creatinine index 173-177 calculation, S2:67 Diabetic nephropathy nutritionai status in maintenance dialysis and, $2:23-24 gender differences, vs. ADPKD, 1072-1075 usage, S2:67 incidence, 878-883